Drug Effective For Unapproved Indication in Chattem Inc Drugs

3 drug(s) with this reaction

91 total reports

Overview

Drug Effective For Unapproved Indication has been reported as an adverse reaction across 3 drug(s) manufactured by Chattem Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 91 adverse event reports mention drug effective for unapproved indication in connection with Chattem Inc products.

This page provides a breakdown of which Chattem Inc drugs are most commonly associated with drug effective for unapproved indication, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.

Chattem Inc Drugs Reporting Drug Effective For Unapproved Indication

The following Chattem Inc drugs have drug effective for unapproved indication listed in their FDA adverse event reports, sorted by report count:

Other Reactions Reported for Chattem Inc Drugs

In addition to drug effective for unapproved indication, the following adverse reactions have been reported across Chattem Inc's drug portfolio:

DRUG INEFFECTIVENO ADVERSE EVENTAPPLICATION SITE BURNPAINAPPLICATION SITE PAINBURNING SENSATIONBLISTERSKIN BURNING SENSATIONPAIN IN EXTREMITYDIARRHOEAAPPLICATION SITE ERYTHEMAARTHRALGIAAPPLICATION SITE VESICLESFATIGUENAUSEATHERMAL BURNERYTHEMAHEADACHEDIZZINESSBACK PAIN

Frequently Asked Questions

Which Chattem Inc drugs cause Drug Effective For Unapproved Indication?

3 drug(s) manufactured by Chattem Inc have drug effective for unapproved indication listed in their FDA adverse event reports: DOXYLAMINE SUCCINATE, SELENIUM SULFIDE, CAMPHOR, MENTHOL.

How many Drug Effective For Unapproved Indication reports are there for Chattem Inc drugs?

There are a combined 91 reports of drug effective for unapproved indication across 3 Chattem Inc drug(s) in the FDA adverse event database.

Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.